Ipca Laboratories Limited's receivables is $24B.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
The latest receivables for IPCALAB.BO is $24B as of September 2026. That compares with $21B in the prior-year period — up 14.8% year over year. Investors often review this figure alongside Ipca Laboratories Limited's historical trend and sector peers before judging valuation or financial health.
Over the past year, IPCALAB.BO's receivables moved from $21B to $24B — a 14.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Ipca Laboratories Limited's operating scale or balance-sheet position.
A receivables figure of $24B for IPCALAB.BO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.
After noting IPCALAB.BO's receivables ($24B), review year-over-year change from $21B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.